Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 141 to 150 of 410

Guidance and quality standards awaiting development
Title	Type
Gantenerumab for treating early Alzheimer's disease [TSID10668]	Technology appraisal guidance
Gemcitabine intravesical delivery system for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]	Technology appraisal guidance
Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]	Technology appraisal guidance
Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies	HealthTech guidance
Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [TSID12331]	Technology appraisal guidance
Giredestrant for adjuvant treatment of oestrogen-receptor positive HER2-negative early breast cancer [GID-TA12031	Technology appraisal guidance
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]	Technology appraisal guidance
Glofitamab for treating relapsed or refractory mantle cell lymphoma	Technology appraisal guidance
GNT0006 ATA-100 for treating FKRP-related limb girdle muscular dystrophy R9 [TSID12384]	Technology appraisal guidance
Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]	Technology appraisal guidance

Results per page

10
25
50
All